MedTech is one of the hardest B2B categories to commercialise.
The global medical devices market is worth roughly US$720 billion in 2026 and heading toward US$1.2 trillion by 2035 (Precedence Research).
But individual product launches face long buying cycles, purchasing committees spanning clinical, technical, procurement, and administrative roles, and strict regulatory limits on what marketing can claim.
That combination (huge market, long cycles, committee buying, regulated claims) is precisely the environment where [account-based marketing](/account-based-marketing-strategy "ABM Strategy Guide") (ABM) outperforms volume demand generation.
This guide explains what a MedTech ABM agency, or a MedTech GTM agency, should actually do.
Why ABM fits MedTech
- The target universe is finite. There are only so many hospital systems, IDNs, clinics, and distributors in any territory. Broad-reach lead gen wastes budget on accounts that can never buy.
- Committees, not champions, buy. In ITSMA's 2023 benchmarking study of 279 ABM practitioners, 72% said ABM delivers higher ROI than other types of marketing. Gartner puts the typical buying group for a complex B2B solution at six to 10 decision makers, and ABM engages the whole account rather than one form-filler.
- Buyers self-educate. Gartner's B2B buying research found buyers spend only 17% of the purchase journey meeting potential suppliers. In MedTech, clinicians research evidence independently. Your clinical content, KOL voices, and account-level air cover do the early selling.
- Compliance survives account-level targeting. Company-level intent and engagement tracking avoids the person-level data problems that health-adjacent marketing runs into under GDPR/UK PECR and HIPAA-adjacent US rules.
What a MedTech GTM engagement should include
- Regulatory-aware messaging: claims mapped to your cleared/approved indications (510(k), CE mark, UKCA), reviewed against MDR/FDA advertising rules.
- Account universe build: a named list of target health systems, buying centres, and distributors, enriched with signals (tenders, formulary changes, leadership moves, funding).
- Clinical evidence content: white papers, health-economics one-pagers, and KOL-led material that committee members can circulate internally.
- Multi-channel ABM execution: LinkedIn to named accounts, intent monitoring, conference-synced outbound, and nurture built for long cycles.
- Distributor/channel enablement: much of MedTech revenue flows through channel; your GTM system should arm it, not bypass it.
Choosing between a healthcare specialist and a GTM systems agency
Pure healthcare agencies bring regulatory fluency and clinical networks; GTM systems agencies bring modern data infrastructure (Clay, enrichment, intent) and ABM engineering.
The best results usually come from pairing deep clinical review on your side with an agency that can actually build the account-based engine.
Ask any candidate agency: who reviews claims, how they build the account universe, what signals they track, and what happens to the system when the engagement ends.
Related resources
- ABM Agency UK: the UK account-based marketing landscape
- Account-Based Marketing Strategy: the full ABM playbook
- Best GTM Agencies for Healthcare Tech
- Go-to-Market Strategy Agency: how GTM Quest builds 4-channel systems
- GTM Agency Directory
- Enterprise Sales Strategy: committee selling mechanics
If you are weighing up outside help, start with what a go-to-market agency actually does.
If you are in the UK, also see how a London GTM agency like GTM Quest scopes the work before anyone quotes.